Epidemiology and treatment of acute and chronic heart failure
Abstract
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. This Issue contains three Viewpoint contributions from our ‘Year in Cardiovascular Medicine 2022’ series: ‘The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies’ authored by Johann Bauersachs and Rudolf de Boer;1 ‘The year in cardiovascular medicine 2022: the top 10 papers in arrhythmias’ authored by Harry J.G.M. Crijns, Pier Lambiase, and Prash Sanders;2 and ‘The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology’ authored by Joerg Herrmann, Teresa Lopez-Fernandez, and Alexander Lyon.3 I am sure that the readers will find this series extremely useful. Indeed, in each contribution, the authors, who are Editors of the European Heart Journal, summarize and comment on the ten 10 game-changing original manuscripts published in 2022 in a specific field of cardiovascular medicine. The issue continues with a focus on heart failure (HF) and cardiomyopathies. The choice of myocardial revascularization in stable patients remains controversial.4–10 In a Fast Track clinical research article entitled ‘Surgical or percutaneous coronary revascularization for heart failure: an in silico model using routinely collected health data to emulate a clinical trial’, Suraj Pathak from the University of Leicester in the UK, and colleagues note that the choice of revascularization with coronary artery bypass grafting (CABG)…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 5,988 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.